TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03037047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolate injection
Description: Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
Study: NCT00516139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Open-label
Study: NCT00466609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine (fluoxetine plus clomipramine)
Description: Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine (fluoxetine plus quetiapine)
Description: Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fluoxetine plus placebo)
Description: Placebo plus fluoxetine at maximum dosage of 80mg per day
Study: NCT03142347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote endarterectomy
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote endarterectomy + DCB balloon
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
Study: NCT01479270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
Study: NCT03422445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib：500mg/d，qd，po，d1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide：300mg/d，qd，po，d1-5
Study: NCT01065467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Taken orally three times per week.
Study: NCT00174837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: in combination with cisplatin and concomitant radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: with concomitant radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: with concomitant radiation
Study: NCT03148522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: receive escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: receive duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: receive mirtazapine
Study: NCT01913145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A1c, Self-collection, Blood sample
Description: This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
Study: NCT00529477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1. Wright Nebulizer
Description: The Wright nebulizer will be used to perform the methacholine challenge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pari LC Nebulizer
Description: The Pari LC nebulizer will be used to perform the methacholine challenge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Pari Sinustar Nebulizer
Description: The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
Study: NCT05058053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
Study: NCT02843451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03832972

Intervention type: OTHER
Intervention: estrogen level
Description: Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen

Intervention type: OTHER
Intervention: estrogen level
Description: Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
Study: NCT00777075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00460018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, Exercise, and Breastfeeding Intervention
Description: Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)
Study: NCT02778672

Intervention type: OTHER
Intervention: Thermal imaging of infant's chest with a mobile phone
Study: NCT03367598

Intervention type: GENETIC
Intervention: rs662799 (APOA5 -1131T>C)
Description: Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.

Intervention type: GENETIC
Intervention: rs662799 (APOA5 -1131T>C)
Description: Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.
Study: NCT03209869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded and Activated Haploidentical Donor NK Cells
Description: Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu14.18-IL2
Description: The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
Study: NCT01454739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.
Study: NCT02761798

Intervention type: DEVICE
Intervention: Automated Mobile Interactive Audiometer
Description: iPad game

Intervention type: DEVICE
Intervention: Automated Mobile Interactive Audiometer
Description: iPad game

Intervention type: DEVICE
Intervention: Automated Mobile Interactive Audiometer
Description: iPad game

Intervention type: DEVICE
Intervention: Automated Mobile Interactive Audiometer
Description: iPad game
Study: NCT04556812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four-in-one procedure
Description: four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: soft-tissue surgery
Description: traditional soft-tissue surgery
Study: NCT01467310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 1.5 to 2.0 mg taken orally every day for seven days.
Study: NCT03790709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ANAVEX2-73
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid dose ANAVEX2-73
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsule
Study: NCT01643486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iTouch phosphate counting program
Description: After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
Study: NCT03210012

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Diagnostic test done prior and after the dive

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Diagnostic test done prior and after the dive
Study: NCT01177761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
Study: NCT01952847

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Study: NCT01089010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT04483284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with Camrelizumab
Description: Camrelizumab(200mg q3w ivgtt) combined with TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE plus Camrelizumab
Description: Camrelizumab(200mg q3w ivgtt) combined with TACE
Study: NCT01633970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Participants will receive 5-FU 400 mg/m\^2 IV q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Participants will receive leucovorin 400 mg/m\^2 IV q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 200 mg/m\^2 IV q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
Study: NCT02283320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
Study: NCT02461680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tangential resection
Description: the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Study: NCT04102384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO App
Description: The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
Study: NCT02390713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-AVR
Description: Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography.
Study: NCT04631237

Intervention type: OTHER
Intervention: Observational, no intervention
Description: No intervention involved

Intervention type: OTHER
Intervention: Observational, no intervention
Description: No intervention involved

Intervention type: OTHER
Intervention: Observational, no intervention
Description: No intervention involved
Study: NCT02061423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed Dendritic Cell Vaccine
Description: Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
Study: NCT02776670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol, 0.6% eye drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant eye drops
Study: NCT00323076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET Imaging
Description: Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.
Study: NCT03699540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Experimental, non-therapeutic administration of active marijuana dose(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Experimental, non-therapeutic administration of active alcohol dose(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo alcohol
Description: Experimental, non-therapeutic administration of inactive alcohol dose(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive marijuana
Description: Experimental, non-therapeutic administration of inactive marijuana dose(s)
Study: NCT01902511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF+Erythropoetin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study: NCT00565227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (suberoylanilide hydroxamic acid)
Description: Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
Study: NCT01952847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.